X4 Pharmaceuticals, INC Form 4 insider transactions

X4 Pharmaceuticals CFO David Kirske sold 8,543 shares of common stock for tax obligations.

X4 Pharmaceuticals reports that Director Kelly Gold was granted 110,000 stock options with an exercise price of $4.085.

X4 Pharmaceuticals CFO David Kirske reported a sale of 16,961 common shares on May 12, 2026, for tax obligations.

X4 Pharmaceuticals, Inc. Director Gary Bridger was granted 110,000 stock options with an exercise price of $4, vesting upon shareholder approval.

X4 Pharmaceuticals director Francoise de Craecker was granted 110,000 stock options with a $4 exercise price, vesting upon 2026 stockholder approval.

X4 Pharmaceuticals director Michael S. Wyzga was granted 110,000 stock options with a $4 exercise price, vesting upon 2026 stockholder approval.

X4 Pharmaceuticals director Murray Stewart was granted 110,000 stock options with a $4 exercise price, contingent on 2026 stockholder approval of a share reserve increase.

X4 Pharmaceuticals' Executive Chairman, Adam R. Craig, was granted 2.3 million stock options with a performance-based vesting condition satisfied.

X4 Pharmaceuticals President John Volpone was granted 2.3 million stock options with a $1.42 exercise price, vesting over 24 months.

X4 Pharmaceuticals' CFO, David Kirske, acquired 1,552,769 stock options with a $1.42 exercise price after a performance condition was met.

X4 Pharmaceuticals' Executive Chairman, Adam R. Craig, purchased 86,206 shares of common stock at $2.90 per share, increasing his direct beneficial ownership.

X4 Pharmaceuticals' President, John Volpone, received significant equity grants including restricted stock units and stock options, aligning his incentives with long-term company performance.

X4 Pharmaceuticals' Executive Chairman, Adam R. Craig, was granted significant equity awards, including restricted stock units and stock options.

X4 Pharmaceuticals' Chief Financial Officer, David Kirske, was granted 193,254 restricted stock units and 1,426,049 stock options as part of his compensation.

X4 Pharmaceuticals, Inc. has granted 3,333 restricted stock units to its Chief Legal Officer, Natasha Fay Thoren, as part of the company's equity incentive plan.

X4 Pharmaceuticals, Inc. Director Murray Stewart was granted 1,500 restricted stock units (RSUs) as part of his annual compensation for board service, aligning his interests with shareholders.

X4 Pharmaceuticals, Inc. Director Francoise de Craecker was granted 1,500 restricted stock units as part of her annual compensation for board service, vesting over one year or upon the next annual meeting.

X4 Pharmaceuticals, Inc. Director Gary Bridger was granted 1,500 restricted stock units as an annual award for his service on the Board of Directors.

X4 Pharmaceuticals, Inc. Director Keith Woods reported the acquisition of 1,500 restricted stock units (RSUs) as an annual award for his board service, vesting based on continued service or a change in control.

X4 Pharmaceuticals, Inc. Director David W.J. McGirr was granted 1,500 restricted stock units (RSUs) as an annual award for his board service, increasing his direct beneficial ownership to 4,722 shares.

X4 Pharmaceuticals, Inc. Director Michael S. Wyzga was granted 1,500 restricted stock units as an annual award for his board service, increasing his beneficial ownership to 5,555 shares.

X4 Pharmaceuticals' Chief Commercial Officer, Mark Baldry, filed an amended Form 4 to correct the transaction code for a recent purchase of 1,032 shares of common stock made through the company's Employee Stock Purchase Plan.

Mark Baldry, Chief Commercial Officer of X4 Pharmaceuticals, acquired 1,032 shares of common stock through the company's employee stock purchase plan at $2.482 per share.

Christophe Arbet-Engels, Chief Medical Officer of X4 Pharmaceuticals, was granted 850,000 restricted stock units under the company's equity incentive plan.

Adam S. Mostafa, CFO of X4 Pharmaceuticals, was granted 850,000 restricted stock units under the company's equity incentive plan.

Paula Ragan, CEO of X4 Pharmaceuticals, was granted 2,250,000 restricted stock units under the company's equity incentive plan.

Mark Baldry, Chief Commercial Officer of X4 Pharmaceuticals, reports purchases of common stock and a grant of restricted stock units.

Mary DiBiase, COO of X4 Pharmaceuticals, was granted 650,000 restricted stock units under the company's equity incentive plan.

X4 Pharmaceuticals CEO Paula Ragan acquired shares through vesting of performance-based restricted stock units and sold a portion of her holdings under a pre-arranged trading plan.

X4 Pharmaceuticals' Chief Financial Officer, Adam S. Mostafa, sold 74,773 shares of common stock after the vesting of performance-based restricted stock units.